James E Egan1,2, Ken Ho3, Ron Stall1,2, Moe T Drucker4, Ryan Tappin4, Craig W Hendrix5, Mark A Marzinke5, Steven A Safren4,6, Matthew J Mimiaga4,7, Christina Psaros8, Steven Elsesser4,9, Kenneth H Mayer4,10. 1. Department of Behavioral and Community Health Sciences, Graduate School for Public Health, University of Pittsburgh, Pittsburgh, PA. 2. Center for LGBT Health Research, University of Pittsburgh, Pittsburgh, PA. 3. Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 4. Fenway Health, Boston, MA. 5. Johns Hopkins University School of Medicine, Baltimore, MD. 6. University of Miami, Miami, FL. 7. Brown University, Schools of Public Health and Medicine, Providence, RI. 8. Department of Psychiatry, Massachusetts General Hospital, Boston, MA. 9. Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA; and. 10. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate is efficacious in reducing HIV acquisition. For some gay, bisexual, and other men who have sex with men (MSM), daily ongoing PrEP may be unsuitable for use as a long-term prevention strategy because of episodic risk, cost issues, or concerns about the biological consequences of medication. SETTING: This study evaluated the feasibility of short-term, fixed-interval episodic PrEP (Epi-PrEP) for use among vacationing MSM. We describe the feasibility of implementing a clinic-based Epi-PrEP pilot program for 48 MSM who reported occasional condomless sex and anticipated a defined high-risk time. METHODS: This was a nonrandomized naturalistic study of an observational clinical intervention. The primary outcome assessed was adherence, as measured by self-report and plasma tenofovir levels. RESULTS: Of 54 MSM who enrolled in the study, 48 completed the 3-month visit. The majority (93.7%) had tenofovir concentrations consistent with daily use on returning from vacation. Almost 3/4 reported condomless sex during vacation, and about 1/3 reported recreational drug use. During the 3-month follow-up, 1 participant had become HIV-infected because of a lapse in continued access to the PrEP after study. Although adverse events were common, none were serious. More than 70% of participants indicated an interest in daily ongoing PrEP use. CONCLUSIONS: Epi-PrEP was well tolerated by at risk MSM in this study, with high levels of medication adherence. Many participants felt the experience of initiating PrEP while on vacation could be a means for transition to long-term PrEP use.
BACKGROUND: Pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate is efficacious in reducing HIV acquisition. For some gay, bisexual, and other men who have sex with men (MSM), daily ongoing PrEP may be unsuitable for use as a long-term prevention strategy because of episodic risk, cost issues, or concerns about the biological consequences of medication. SETTING: This study evaluated the feasibility of short-term, fixed-interval episodic PrEP (Epi-PrEP) for use among vacationing MSM. We describe the feasibility of implementing a clinic-based Epi-PrEP pilot program for 48 MSM who reported occasional condomless sex and anticipated a defined high-risk time. METHODS: This was a nonrandomized naturalistic study of an observational clinical intervention. The primary outcome assessed was adherence, as measured by self-report and plasma tenofovir levels. RESULTS: Of 54 MSM who enrolled in the study, 48 completed the 3-month visit. The majority (93.7%) had tenofovir concentrations consistent with daily use on returning from vacation. Almost 3/4 reported condomless sex during vacation, and about 1/3 reported recreational drug use. During the 3-month follow-up, 1 participant had become HIV-infected because of a lapse in continued access to the PrEP after study. Although adverse events were common, none were serious. More than 70% of participants indicated an interest in daily ongoing PrEP use. CONCLUSIONS: Epi-PrEP was well tolerated by at risk MSM in this study, with high levels of medication adherence. Many participants felt the experience of initiating PrEP while on vacation could be a means for transition to long-term PrEP use.
Authors: Kenneth H Mayer; Philip A Chan; Rupa R Patel; Charlene A Flash; Douglas S Krakower Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Cristian J Chandler; Leigh A Bukowski; Derrick D Matthews; Mary E Hawk; Nina Markovic; Ronald D Stall; James E Egan Journal: AIDS Care Date: 2019-08-28
Authors: Kenneth H Mayer; Steven A Safren; Steven A Elsesser; Christina Psaros; Jake P Tinsley; Mark Marzinke; William Clarke; Craig Hendrix; S Wade Taylor; Jessica Haberer; Matthew J Mimiaga Journal: AIDS Behav Date: 2017-05
Authors: Conor Stack; Catie Oldenburg; Matthew Mimiaga; Steven A Elsesser; Douglas Krakower; David S Novak; James E Egan; Ronald Stall; Steve Safren; Kenneth H Mayer Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731
Authors: G N Colfax; G Mansergh; R Guzman; E Vittinghoff; G Marks; M Rader; S Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2001-12-01 Impact factor: 3.731
Authors: Nicolette A Louissaint; Ying-Jun Cao; Paul L Skipper; Rosa G Liberman; Steven R Tannenbaum; Sridhar Nimmagadda; Jean R Anderson; Stephanie Everts; Rahul Bakshi; Edward J Fuchs; Craig W Hendrix Journal: AIDS Res Hum Retroviruses Date: 2013-05-29 Impact factor: 2.205
Authors: Steven A Elsesser; Catherine E Oldenburg; Katie B Biello; Matthew J Mimiaga; Steven A Safren; James E Egan; David S Novak; Douglas S Krakower; Ron Stall; Kenneth H Mayer Journal: AIDS Behav Date: 2016-07
Authors: Pablo K Valente; Jose A Bauermeister; Willey Y Lin; Don Operario; Jack Rusley; Lisa Hightow-Weidman; Kenneth H Mayer; Katie B Biello Journal: AIDS Behav Date: 2022-04-21